Exploring mTOR inhibition as treatment for mitochondrial disease
Abstract Leigh syndrome and MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke‐like episodes) are two of the most frequent pediatric mitochondrial diseases. Both cause severe morbidity and neither have effective treatment. Inhibiting the mammalian target of rapamycin (mTOR) pathway...
Main Authors: | Abigail Sage‐Schwaede, Kristin Engelstad, Rachel Salazar, Angela Curcio, Alexander Khandji, James H. Garvin Jr, Darryl C. De Vivo |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-09-01
|
Series: | Annals of Clinical and Translational Neurology |
Online Access: | https://doi.org/10.1002/acn3.50846 |
Similar Items
-
Dose-dependent Effects of mTOR Inhibition on Weight and Mitochondrial Disease in Mice
by: Simon C Johnson, et al.
Published: (2015-07-01) -
mTOR Inhibition and Tuberous Sclerosis Prevention
by: J Gordon Millichap
Published: (2013-09-01) -
Tumour cell responses to mTOR inhibition
by: Joyce, Claire Lois
Published: (2012) -
mTOR signaling pathway and mTOR inhibitors in the treatment of cancer
by: Mehmet Küçüköner, et al.
Published: (2013-03-01) -
Activated mTOR signaling pathway in myofibers with inherited metabolic defect might be an evidence for mTOR inhibition therapies
by: Jing-Wei Lyu, et al.
Published: (2019-04-01)